Page 23 - Flipbook

International Prostate Cancer Guidelines Have Been Updated To Provide

Recommendations for Molecular Testing and Treatment with PARP Inhibitors 1-8

FDA approval of olaparib Health Canada
19 May 2020 ESMO Guidelines approval of olaparib

26 June 2020 21 August 2020

NCCN NCCN
®
®
Guidelines V.1.2020 Guidelines V.2.2020 AUA/ASTRO/SUO Guidelines
16 March 2020 21 May 2020 27 June 2020

CUA/CUOG 2021
Philadelphia Consensus
EAU Guidelines Published 9 June 2020 1 Feb 2021

25 March 2020 Meeting: 4 October 2019

March April May June July August September October February
2020 2020 2021

APCCC, Advanced Prostate Cancer Consensus Conference; ASTRO, American Society for Radiation Onology; AUA, American Urological Association; CUA, Canadian Urological Association; CUOG, Canadian Uro Oncology
Group; EAU, European Association of Urology; ESMO, European Society for Medical Oncology; mCRPC, metastatic casstration-resistant prostate cancer; NCCN, National Comprehensive Cancer Network; SUO, Society of Urologic
Oncology. 1. NCCN Guidelines in Clinical Oncology. Prostate Cancer. V1.2020; 2. NCCN Guidelines in Clinical Oncology. Prostate Cancer. V2.2020; 3. EAU Prostate Cancer Guidelines. https://uroweb.org/guideline/prostate-cancer/;
4. Giri VN et al. J Clin Oncol 2020;38:2798-811; 5. Parker C et al. Ann Oncol 2020;31:1119-34; 6. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline: https://www.auanet.org/guidelines/advanced-prostate-cancer; 7. Lynparza
(olaparib) US PI; 8. Lynparza (olaparib) Product Monograph; 8. Saad F et al. CUAJ 2021;15:E81-90.